Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $14.00 Average Price Target from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have earned an average recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $14.00.

A number of research firms have commented on ATRA. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. Mizuho raised Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price objective for the company from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, The Goldman Sachs Group lowered their target price on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research note on Wednesday, July 17th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATRA. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $53,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $79,000. Delap Wealth Advisory LLC purchased a new stake in shares of Atara Biotherapeutics in the first quarter valued at approximately $29,000. BNP Paribas Financial Markets grew its holdings in Atara Biotherapeutics by 29.3% during the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 86,842 shares during the period. Finally, Acadian Asset Management LLC raised its position in Atara Biotherapeutics by 49.5% in the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after acquiring an additional 873,133 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Stock Performance

ATRA opened at $8.60 on Thursday. The stock has a market capitalization of $41.43 million, a P/E ratio of -0.16 and a beta of 0.50. Atara Biotherapeutics has a one year low of $4.96 and a one year high of $39.50. The business’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $10.93.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million during the quarter, compared to the consensus estimate of $48.30 million. On average, equities research analysts forecast that Atara Biotherapeutics will post -12.09 EPS for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.